pSivida Corp.  

(Public, NASDAQ:PSDV)   Watch this stock  
Find more results for PSDV
3.00
-0.04 (-1.32%)
Real-time:   12:03PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.00 - 3.06
52 week 2.37 - 5.81
Open 3.01
Vol / Avg. 19,350.00/74,373.00
Mkt cap 105.65M
P/E     -
Div/yield     -
EPS -0.67
Shares 34.17M
Beta 1.31
Inst. own 44%
May 5, 2016
Q3 2016 pSivida Corp Earnings Call
May 5, 2016
Q3 2016 pSivida Corp Earnings Release
Mar 31, 2016
pSivida Corp at Sidoti Emerging Growth Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1555.86% 23.89%
Operating margin -1572.84% 24.17%
EBITD margin - 27.49%
Return on average assets -67.27% 23.06%
Return on average equity -98.69% 33.15%
Employees 26 -
CDP Score - -

Address

480 Pleasant St Ste B300
WATERTOWN, MA 02472-2468
United States - Map
+1-617-9265000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

pSivida Corp. is a biotechnology company, which is engaged in the development of sustained-release drug-delivery products for treating eye diseases. The Company offers products for treatment of back-of-the-eye diseases. The Company's lead development product, Medidur is used for posterior of the eye (posterior uveitis). Medidur is in Phase III clinical trials. The Company's pre-clinical development program is focused on developing products using its platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat ophthalmic diseases, such as wet and dry age-related macular degeneration (AMD), glaucoma and osteoarthritis, among others. Its Durasert technology platform delivers therapeutics for predetermined periods of time ranging from days to years. Its Tethadur technology system utilizes BioSilicon, nanostructured elemental silicon, designed to provide sustained delivery of biologic molecules, such as peptides, proteins and antibodies.

Officers and directors

David J. Mazzo Ph.D. Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Paul Ashton President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Leonard S. Ross Vice President - Finance, Principal Financial Officer
Age: 65
Bio & Compensation  - Reuters
Lori Freedman Vice President - Corporate Affairs, General Counsel, Company Secretary
Age: 48
Bio & Compensation  - Reuters
James J. Barry Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Douglas Evan Godshall M.B.A. Independent Director
Age: 50
Bio & Compensation  - Reuters
Michael W. Rogers Independent Director
Age: 55
Bio & Compensation  - Reuters